Clinical Trials · NCT06878664
Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors
- Phase
- Phase 3
- Recruitment status
- Recruiting
- Sponsor
- Grupo Espanol de Tumores Neuroendocrinos
- Enrollment
- 166
- Start date
- Jun 2025
- Locations
- 21 sites, France, Spain
- Primary endpoint
- Rate of Grade 2-5 hematological toxicity